BackgroundTrichosporon species may colonize the skin, respiratory tract and gastrointestinal tract of human beings. The yeast is recognized as etiological agent of white piedra, a superficial mycosis. Nevertheless, immunocompromised hosts may develop invasive Trichosporonosis. Central nervous system trichosporonosis is a very rare clinical manifestation. In fact, only a few cases have been published in the literature and none of them was caused by Trichosporon inkin.Case presentationHere we report the first clinical case of meningoencephalitis due to this species in a female previously healthy patient under corticosteroids and antibiotics therapy for several months. She was submitted to an invasive procedure to remove a left sided acoustic neuroma and further developed a cerebrospinal fistula. After some days of the procedure, she presented a predominantly and intensive occipital holocranial headache, followed by vomiting, hyporexia, weight loss, asthenia, irritability, difficulty to concentrate and rotator vertigo. The patient further developed a cerebrospinal fistula in the occipital region and was submitted to a surgical correction. After several months of clinical interventions, she was diagnosed with CNS Trichosporonosis, after Magnetic Resonance Imaging and positive microbiological cultures obtained within two different occasions (2 weeks apart). Despite the antifungal therapy with Amphotericin B and Voriconazole, the patient did not survive.ConclusionsDespite CNS Fungal infections are mostly due to Cryptococcus spp., other emergent yeasts, such as T. inkin may be considered as a likely etiological agent. This is the first case report of CNS Trichosporonosis, where species identification was performed with rDNA sequencing.
Objective: Examining the effects of simvastatin on skeletal muscles in an experimental model of abdominal sepsis in rats through the biodistribution of 99mTc-sestamibi. Methods: Wistar rats were randomly assigned to 2 groups: with abdominal sepsis (n = 12) and without sepsis (n = 12). Six animals with sepsis and 6 controls were injected with a daily dose of 5 mg/kg/day of simvastatin by gavage for 3 days before induction of peritonitis and 4 hours before surgical procedure. The others received 1ml of 0.9% saline solution orally. The animals were anesthetized with 20mg/kg of xylazine and 50mg/kg of ketamine i.p. Cecal ligation and puncture were performed by laparotomy. The rats were under observation for 24 hours and their survival time was recorded. The animals were re-anesthetized and 0.1 ml of 99mTc-sestamibi was administered by i.v. 30 minutes later,the thigh muscle was biopsied for percentage of radioactivity per gram of tissue (ATI%/g) determination, measured by the automatic gamma counter Wizard Counter, PerkinElmer,Finland. Results: ATI%/g of Tc99m-sestamibi was higher in muscle samples of groups treated with simvastatin sepsis ((1.820.21), compared with saline-treated (1.070.19) and control groups (1.180.31;1.260.24); this is a statistically significant difference (p<0.001). Conclusion: The data resulting from this study allows for concluding that the pre-treatment with simvastatin contributed to a biodistribution increase of 99mTc-sestamibi into the skeletal muscle in the abdominal sepsis model in rats.
Cryptosporidiosis is a very prominent disease in the fi eld of public health, and usually causes diarrhea. We describe two immunocompetent patients who presented with chronic diarrhea that was ultimately found to be caused by continuous exposure to well water contaminated with the microbial cysts (oocysts) of the Cryptosporidium spp parasite. We describe the patients' histories and possible explanations for their prolonged symptoms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.